ALX Oncology Holdings Inc. (ALXO)
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Dr. Corey S. Goodman Ph.D. | Executive Chairman | 84k | -- | 1952 |
| Mr. Jason W. Lettmann | CEO & Director | 60.5k | -- | 1977 |
| Dr. Jaume Pons Ph.D. | Founder, President, Director & Chief Scientific Officer | 856.29k | -- | 1967 |
| Mr. Peter S. Garcia M.B.A. | Chief Financial Officer | 631.11k | -- | 1962 |
| Dr. Sophia Randolph M.D., Ph.D. | Chief Medical Officer & Director | 637.24k | -- | 1968 |
| Dr. Michael Chang Ph.D. | Vice President of Operations | -- | -- | -- |
| Ms. Shelly Pinto | Senior VP of Finance & Chief Accounting Officer | 508.26k | -- | 1977 |
| Dr. Christopher Byrd J.D., Ph.D. | General Counsel | -- | -- | -- |
| Dr. Athanasios Tsiatis M.D. | Senior Vice President of Clinical Development | -- | -- | -- |
| Dr. Lin Yeong-Liang M.D., M.S. | Senior Vice President of Drug Safety & Pharmacovigilance | -- | -- | -- |
ALX Oncology Holdings Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 72
Description
ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma. It also has collaboration agreement for Evorpacept combination programs comprising Jazz Pharmaceuticals plc for zanidatamab, under Phase 1 trial for the treatment of breast cancer and other solid tumors; Quantum Leap Healthcare collaborative with an ADC, fam-trastuzumab deruxtecan-nxki, under Phase 1 trial for the treatment of patients with breast cancer; MD Anderson Cancer Center with rituximab and lenalidomide for the treatment of patients with indolent and aggressive NHL; Sanofi with isatuximab and dexamethasone, under Phase 1/2 trial for the treatment of patients with relapsed or refractory multiple myeloma; Academic Gastrointestinal Cancer Consortium with pembrolizumab and cetuximab, under Phase 2 trial to treat refractory microsatellite stable metastatic colorectal cancer; and University of Pittsburgh with liposomal doxorubicin and pembrolizumab, under Phase 2 trial recurrent platinum-resistant ovarian cancer. In addition, the company has collaboration agreement with Tallac Therapeutics, Inc. for the development of ALTA-002, a potent immune activator targeted to myeloid cells in the tumor to promote innate and adaptive anti-cancer immune responses. It also has license agreements with Board of Trustees of the Leland Stanford Junior University, Selexis SA, and Crystal Bioscience, Inc. The company was incorporated in 2015 and is headquartered in South San Francisco, California.
Corporate Governance
Recent Events
- Apr 23, 2024ARS: Annual Report to ShareholdersSee Full Filing
- Apr 22, 2024DEF 14A: Proxy StatementsSee Full Filing
- Mar 08, 2024S-8: Offering RegistrationsSee Full Filing
- Mar 07, 20248-K: Corporate Changes & Voting MattersSee Full Filing
- Dec 26, 20238-K: Corporate Changes & Voting MattersSee Full Filing